Ionis Pharmaceuticals
IONS
326 hedge funds and large institutions have $5.07B invested in Ionis Pharmaceuticals in 2018 Q1 according to their latest regulatory filings, with 53 funds opening new positions, 115 increasing their positions, 103 reducing their positions, and 37 closing their positions.
43% more first-time investments, than exits
New positions opened: 53 | Existing positions closed: 37
12% more repeat investments, than reductions
Existing positions increased: 115 | Existing positions reduced: 103
3% more funds holding
Funds holding: 316 → 326 (+10)
7% more call options, than puts
Call options by funds: $44.9M | Put options by funds: $42M
0.65% more ownership
Funds ownership: 91.17% → 91.83% (+0.65%)
11% less capital invested
Capital invested by funds: $5.72B → $5.07B (-$650M)
20% less funds holding in top 10
Funds holding in top 10: 5 → 4 (-1)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BB
BB Biotech
Schaffhausen,
Switzerland
|
+$19.3M |
| 2 |
Two Sigma Investments
New York
|
+$17.1M |
| 3 |
CS
Credit Suisse
Zurich,
Switzerland
|
+$15.3M |
| 4 |
Vanguard Group
Malvern,
Pennsylvania
|
+$13.7M |
| 5 |
SI
Scout Investments
Kansas City,
Missouri
|
+$12.4M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Wellington Management Group
Boston,
Massachusetts
|
-$47.9M |
| 2 |
FCM
Farallon Capital Management
San Francisco,
California
|
-$32.4M |
| 3 |
Baillie Gifford & Co
Edinburgh,
United Kingdom
|
-$17.8M |
| 4 |
TAM
Tocqueville Asset Management
New York
|
-$12.7M |
| 5 |
SGAM
Smith Group Asset Management
Dallas,
Texas
|
-$8.88M |
IONS Hedge Fund Activity: Q1 2018 in Review
326 of the 4,364 institutional investors tracked by Wall St. Rank reported a position in Ionis Pharmaceuticals (IONS) for Q1 2018, worth a combined $5.07B — down 11% from $5.72B a quarter earlier.
Buyers outnumbered sellers: 53 funds opened new IONS positions and 37 closed out — a net gain of 16 holders — while 115 added to existing stakes and 103 trimmed.
The largest buyer was BB Biotech, adding an estimated $19.3M. The largest seller was Wellington Management Group, cutting an estimated $47.9M.
- 326 institutional investors held Ionis Pharmaceuticals (IONS) as of Q1 2018, up from 316 in Q4 2017.
- Funds reported $5.07B of Ionis Pharmaceuticals stock for Q1 2018, down 11% quarter-over-quarter.
- 53 funds opened new Ionis Pharmaceuticals positions in Q1 2018 and 37 closed out, a net change of +16 holders.
- The largest Ionis Pharmaceuticals buyer in Q1 2018 was BB Biotech, an estimated $19.3M added.
- The largest Ionis Pharmaceuticals seller in Q1 2018 was Wellington Management Group, an estimated $47.9M sold.
Based on aggregated 13F filings for Q1 2018.